Surgiphor 1,000mL allows clinicians to remove debris and microorganisms from wounds during powered irrigation procedures.

Over the last six months, BD’s shares have sunk to $160.20, producing a disappointing 14.6% loss while the S&P 500 was flat.

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...

Waters Corp. and BD announced a definitive agreement July 14 to combine BD’s Biosciences & Diagnostic Solutions businesses with the Milford, Mass.-based company. The deal is structured as a ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...

Becton, Dickinson and Company ( BDX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDT Good morning. Thanks very much for joining us. Very pleased today to have with us Tom ...

Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Becton, Dickinson and Co. plans to invest more than $110 million to expand a prefilled flush syringe manufacturing facility in Nebraska. According to BD, the plan aims to better meet growing demand ...